TY - JOUR
T1 - Persistent insomnia is associated with mortality risk
AU - Parthasarathy, Sairam
AU - Vasquez, Monica M.
AU - Halonen, Marilyn
AU - Bootzin, Richard
AU - Quan, Stuart F.
AU - Martinez, Fernando D.
AU - Guerra, Stefano
N1 - Funding Information:
Conflicts of Interest: No conflicts exist for either MMV or MH. SP has received grant monies to institution from Philips-Respironics, Inc. (for sleep apnea therapy device); Younes Sleep Technologies (sleep analysis software), and Niveus Medical Inc. (muscle stimulation device for critically ill patients); however, this is not related to the content matter of this manuscript. SP has received an honorarium from Philips-Respironics, Inc., for participation in a roundtable discussion about obesity-hypoventilation syndrome. SG has received speaker compensation from Medimmune, however, this is not related to the content matter of this manuscript. SG has received University of Arizona federal grant monies (National Institutes of Health [NIH]). SQ has served as a consultant to Saatchi and Saatchi and has received grant monies (NIH) to Brigham and Women's Hospital. RB is consultant and chair of the Science Advisory Board for General Sleep Corporation. FDM has received University of Arizona federal grant monies (NIH). FDM also served as a consultant to MedImmune in 2010, and was invited by Merck (2011) and Abbott (2011 and 2012) as a guest lecturer.
Funding Information:
Funding: Funding support came from the National Institutes of Health (NIH)/ National Heart, Lung, and Blood Institute . This work was supported by the NIH Grants 5R01HL095748 , 5R01HL095021 , and CADET award HL107188 . The funding institutions did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18%) had intermittent and 128 (9%) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95% confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95% CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95% CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.
AB - Background Insomnia has been associated with mortality risk, but whether this association is different in subjects with persistent vs intermittent insomnia is unclear. Additionally, the role of systemic inflammation in such an association is unknown. Methods We used data from a community-based cohort to determine whether persistent or intermittent insomnia, defined based on persistence of symptoms over a 6-year period, was associated with death during the following 20 years of follow-up. We also determined whether changes in serum C-reactive protein (CRP) levels measured over 2 decades between study initiation and insomnia determination were different for the persistent, intermittent, and never insomnia groups. The results were adjusted for confounders such as age, sex, body mass index, smoking, physical activity, alcohol, and sedatives. Results Of the 1409 adult participants, 249 (18%) had intermittent and 128 (9%) had persistent insomnia. During a 20-year follow-up period, 318 participants died (118 due to cardiopulmonary disease). In adjusted Cox proportional-hazards models, participants with persistent insomnia (adjusted hazards ratio [HR] 1.58; 95% confidence interval [CI], 1.02-2.45) but not intermittent insomnia (HR 1.22; 95% CI, 0.86-1.74) were more likely to die than participants without insomnia. Serum CRP levels were higher and increased at a steeper rate in subjects with persistent insomnia as compared with intermittent (P =.04) or never (P =.004) insomnia. Although CRP levels were themselves associated with increased mortality (adjusted HR 1.36; 95% CI, 1.01-1.82; P =.04), adjustment for CRP levels did not notably change the association between persistent insomnia and mortality. Conclusions In a population-based cohort, persistent, and not intermittent, insomnia was associated with increased risk for all-cause and cardiopulmonary mortality and was associated with a steeper increase in inflammation.
KW - Cardiovascular
KW - Chronic insomnia
KW - Mortality
KW - Sleep
UR - http://www.scopus.com/inward/record.url?scp=84924208308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924208308&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2014.10.015
DO - 10.1016/j.amjmed.2014.10.015
M3 - Article
C2 - 25447616
AN - SCOPUS:84924208308
SN - 0002-9343
VL - 128
SP - 268-275.e2
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 3
ER -